Researchers have made a groundbreaking discovery into why some forms of breast cancer are drug resistant. 

Cancer scientists at City St George’s, University of London found a ‘molecular signature’ drives drug resistance in an aggressive type of breast cancer known as HER2-positive breast cancer. 

The study, published in the British Journal of Cancer, identified nine key red flags that appear to accelerate resistance to the drug lapatinib in HER2-positive breast cancer cells. Remarkably, seven of these had never been linked to HER2-positive breast cancer or lapatinib resistance before.

The results may explain why these patients develop resistance to the drug lapatinib – a targeted therapy used when other treatments fail. Lapatinib works by shutting down key processes inside cancer cells, slowing their growth and, in some cases, killing them altogether.

The team says the results present a possible way forward for a new era of breast cancer treatments. 

“Over 70% of breast cancer patients relapse within five years of treatment, and drug resistance remains one of the biggest challenges in cancer care,” said Dr Ateequllah Hayat, Lecturer in Drug Development from the School of Health & Medical Sciences at City St George’s, University of London, who led the study. 

“By combining several advanced techniques, we were able to uncover subtle but critical changes in the cancer cells that were previously invisible.” 

‘Molecular maps’ help pinpoint drivers of drug resistance 


To gain a detailed picture of how resistance to lapatinib develops, researchers used a powerful combination of techniques to examine the molecular profile of HER2 breast cancer cells and lapatinib-resistance HER2 cells.  

Scientists analysed the cells at multiple levels – examining how tightly or loosely the DNA was packaged by measuring the accessibility of DNA structures called chromatin, identified which genes were switched on or off, and determined which proteins were produced by the cells.

These three ‘molecular maps’ were layered on top of each other to determine the most consistent changes, and therefore those most likely to be true drivers of drug resistance. 

The team discovered that lapatinib-resistant HER2 cancer cells exhibit a paradoxical behaviour. While their DNA was more tightly packaged overall with a reduction in chromatin accessibility compared to normal HER2 cancer cells, specific regions of DNA near key genes responsible for drug resistance to lapatinib were more open and active.

A total of nine genetic markers were consistently altered in breast cancer resistance. Seven new markers, HPGD, FASN, TPM1, CALD1, PCP4, AKR7A3 and KRT81, were discovered to be linked to breast cancer or lapatinib resistance for the first time, and EGFR and SCIN were already known to be involved in resistance. These regions were linked to increased stress responses, actin remodelling and metabolic reprogramming, all of which could help cancer cells adapt to treatment. 

The lapatinib-resistance HER2 cells were also found to be more irregular and less spherical in shape compared to normal HER2 cells, with protrusions that could help aggressively invade healthy cells. 

Analysis ‘opens the door’ to biomarker-guided therapies 


The researchers then looked at lung cancer cells and found that two of the genes associated with resistance mechanisms – FASN and HPGD – were also increased with lapatinib resistance. 

“Our results suggest that our nine-marker resistance signature may be found in other types of cancer beyond breast cancer,” Hayat added. 

“This work opens the door to developing biomarker-guided therapies that could prevent or reverse drug resistance. It’s a major step toward more personalised and effective cancer treatments to give patients more options. 

“Ultimately, the hope is that resistance will no longer be an inevitable outcome, but rather a predictable process that can be prevented.”